VHH Polypeptides Targeting CD123 to Overcome Leukemia Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CD123-expressing cancers, such as leukemia, are inadequate due to resistance and poor prognosis associated with high CD123 expression, necessitating more potent therapeutic options.
Innovation Solution
Development of CD123-binding polypeptides, specifically comprising VHH domains with defined CDR sequences, that can bind to CD123, potentially blocking its interaction with IL-3 and used in conjunction with cytotoxic agents or as part of immunoconjugates to target cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for CD123-expressing cancers, then treatment is provided, but treatment efficacy is insufficient due to resistance and poor prognosis
Solution Approach 1:
The patent uses VHH domains as intermediary binding proteins that specifically target CD123 on cancer cells. These VHH domains act as mediators between the immune system and cancer cells, enabling targeted delivery of cytotoxic agents or activation of immune responses against CD123-expressing leukemia cells while sparing normal cells
Solution Approach 2:
The patent employs affinity maturation and sequence optimization to enhance the binding affinity and specificity of VHH domains for CD123. By modifying amino acid sequences in CDR regions and optimizing structural parameters, the VHH domains achieve higher potency and overcome cancer cell resistance mechanisms that render conventional treatments ineffective
2Ease of operation
If CD123-binding polypeptides are developed to target cancer cells, then treatment specificity is improved, but polypeptide structure complexity increases
Solution Approach 1:
The patent utilizes VHH domains, which are segmented single-domain antibody fragments derived from heavy-chain-only antibodies. These compact domains contain only the variable region necessary for antigen binding, eliminating the need for full antibody structures with constant regions and light chains, thereby simplifying the overall polypeptide architecture while maintaining targeting capability
Solution Approach 2:
The patent extracts and utilizes only the essential antigen-binding variable domain (VHH) from complete antibody structures. By taking out just the functional binding portion and removing unnecessary constant regions and light chains, the design achieves simplified polypeptide structures that retain CD123 targeting ability while reducing structural complexity and improving pharmacokinetic properties
Data Source
AI summary
Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.